Saban Sec
- 専門分野: Clinical oncologist
- 14年の経験
- 話します:Turkish
- 勤務先: トルコ, イスタンブール, Valued Med Hub Hospitals
- Turkish Medical Oncology Association Specialist Physicians Representative since 2022. Member of Istanbul Medical Chamber and Turkish Medical Oncology Association.
Dr. Saban Sec is a medical oncologist at Valued Med Hub Hospitals in Istanbul. He treats breast, lung, gastrointestinal, and rare tumors. Dr. Sec currently represents specialist physicians in the Turkish Medical Oncology Association. He conducted a significant clinical study involving 138 patients with HER2-positive gastric cancer.
- Expertise covers colorectal, prostate, urogenital, head, neck, and salivary gland cancers.
- Authored over 10 peer-reviewed articles on cancer prognosis and survival rates.
- Member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.
- Treats patients at a clinic holding the International Health Tourism Authorization Certificate.
患者様レビュー
医師のサービス
- PET-CT検査
- 生検
- MRI検査
- CT検査
- 腫瘍マーカー検査
- マンモグラフィ検査
- MRI検査
- 肺生検
- 乳房生検
- 甲状腺機能検査
- 胸部X線検査
- 卵巣生検
- 精巣生検
- 甲状腺生検
- 膵生検
- 肝生検
- 腎生検
- MRI検査
- 脳生検
- 胃内視鏡検査および生検
- 大腸内視鏡検査
- 血管造影検査
調子はいかがですか?
資格
Dr. Saban Sec is a medical oncologist. He is the Specialist Physicians Representative for the Turkish Medical Oncology Association. Dr. Sec treats malignancies including breast, lung, and gastrointestinal cancers. He also treats rare tumors. He currently practices at Valued Med Hub Hospitals in Istanbul.
Clinical Specialization
Dr. Sec treats solid tumors and rare oncological conditions. He provides treatment plans for patients with stage 2 through stage 4 cancers. His interests include:
- Breast and lung cancers
- Gastrointestinal tract cancers including colon, rectum, stomach, and liver
- Prostate and urogenital malignancies
- Head and neck cancers
- Sarcomas and rare tumors
Medical Experience
Dr. Sec has served in several Turkish medical institutions. He has held both specialist and leadership roles during his career.
- 2022–Present — Specialist Physicians Representative at the Turkish Medical Oncology Association
- 2022 — Medical Oncologist at Bahçelievler Medikalpark Hospital
- 2021–2022 — Medical Oncology Specialist at Şanlıurfa Mehmet Akif İnan EAH
- 2017–2021 — Medical Oncology Residency at Prof. Dr. Cemil Taşcıoğlu City Hospital
- 2017 — Internal Medicine Specialist at Kanuni Sultan Süleyman Training and Research Hospital
- 2012–2017 — Internal Medicine Residency at Haseki Training and Research Hospital
Research and Academic Contributions
Dr. Sec conducts clinical research on cancer prognosis and treatment efficacy. He has participated in multicenter studies and analyzed large patient cohorts. His work includes a study of 138 patients with HER2-positive metastatic gastric cancer. He has published research in journals such as Scientific Reports and the European Journal of Internal Medicine.
Dr. Sec also researched the prognostic significance of free T4 and T3 levels in non-thyroidal illness syndrome. He studied how diabetes and fasting plasma glucose affect breast cancer treatment. Furthermore, he investigated the effect of body mass index on colorectal cancer recurrence. He analyzed the efficacy of regorafenib compared to 5-fluorouracil for metastatic colorectal cancer.
Selected Publications
- "Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer"
- "Prognostic significance of mean platelet volume on local advanced non-small cell lung cancer managed with chemoradiotherapy"
- "The predictive role of metabolic tumor volume on no response to neoadjuvant chemotherapy in patients with breast cancer"
- "Factors affecting survival in neuroendocrine tumors: a 15-year single center experience"
- "Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles"
- "Major and minor salivary gland cancers: A multicenter retrospective study"
- "Prognostic significance of primary tumor localization in stage II and III colon cancer"
- "The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy"
- "The effect of body mass index on location of recurrence and survival in early-stage colorectal cancer"
- "Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT"
Professional Memberships
- Turkish Medical Oncology Association
- Istanbul Medical Chamber
こちらもご興味をお持ちいただけるかもしれません
支払い・特典
当社サービスへのお支払いはありません
クリニックで直接またはその公式銀行口座にお支払いいただきます。
一部のクリニックでは保証金が必要な場合があります。
分割払いオプションでお支払いを分散してください。
Bookimedにお友達を紹介して報酬を獲得してください。